LBF20207PG45: Difference between revisions
No edit summary |
No edit summary |
||
| (14 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=XPR1787 | |LipidBank=XPR1787 | ||
|LipidMaps=- | |LipidMaps=- | ||
|SysName= | |SysName=(9alpha,11alpha,15R) -Trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&& | |Common Name=&&15R- Prostaglandin F_2 alpha&&(9alpha,11alpha,15R) -Trihydroxy-prosta- (5Z,13E) -dien-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=In hamster antifertility study, 15(R)-PGF2 alpha is reported quarter potency of PGF2 alpha , which is due to reduced affinity to FP receptors.[[Reference:Miller_WL:Sutton_MJ:,Prostaglandins,1976,11,77|{{RelationTable/GetFirstAuthor|Reference:Miller_WL:Sutton_MJ:,Prostaglandins,1976,11,77}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 08:36, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1787 |
| LipidMaps | - |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG45 |
| 15R- Prostaglandin F2α | |
|---|---|
| |
| Structural Information | |
| (9α,11α,15R) -Trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C20H34O5 |
| Exact Mass | 354.240624198 |
| Average Mass | 354.48096000000004 |
| SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](C[C@@H]1O)O)CC |
| Physicochemical Information | |
| In hamster antifertility study, 15(R)-PGF2 alpha is reported quarter potency of PGF2 alpha , which is due to reduced affinity to FP receptors. Miller_WL et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
